Due to increased nausea and vomiting, dehydration is a major area of concern with GLP-1RA treatments
launch pending approval Zepbound Kwikpen regulatory action Lilly Q1 2026 earnings (early May) Novo Q1 2026 earnings (early May, watch for any GLP-1 psychiatric trial announcements) Q3 and Q4 2026 Retatrutide TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 topline readouts (obesity, OSA) Retatrutide TRANSCEND-T2D readouts (diabetes) Orforglipron ACHIEVE-4 Phase 3 T2D readout Brenipatide for MDD Phase 3 trial initiation Eloralintide Phase 3 initiation 2027 Expected earliest topline results for brenipatide Phase 3 in alcohol use disorder Expected earliest topline results for brenipatide Phase 3 in bipolar disorder Possible regulatory submissions for retatrutide in lead obesity indications Lilly R&D Day announcements expanding the brenipatide program to additional indications (likely) 2028 Earliest realistic FDA decision on brenipatide for AUD assuming successful Phase 3 Phase 2 readouts for brenipatide in smoking, opioid use disorder, and asthma None of these dates are guaranteed
We confirmed this effect using an orthogonal viral strategy: Cre-dependent expression of the danuglipron-sensitive mouse Glp1r S33W variant in CeA neurons reproduced HFD suppression, whereas expression of the WT mouse Glp1r served as an unresponsive control (Extended Data Fig
U osb modszych, szczeglnie poniej 21
A single night at room temperature provides a significant opportunity for any introduced bacteria to multiply, potentially overwhelming the benzyl alcohol preservative
